REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
Go back to REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 7.40 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.40 | 52 Week High | $25.00 | |||
| Open | $7.40 | 52 Week Low | $7.07 | |||
| Day High | $7.40 | P/E | N/A | |||
| Day Low | $7.40 | EPS | $0.00 | |||
| Volume | 247 | |||||
